SLRX Salarius Pharmaceuticals

2.78
+0.05  (+2%)
Previous Close 2.73
Open 2.74
Price To Book 1.16
Market Cap 11,310,486
Shares 4,068,520
Volume 7,451
Short Ratio
Av. Daily Volume 76,159
Stock charts supplied by TradingView

NewsSee all news

  1. Salarius Pharmaceuticals to Present at Biotech Showcase 2020

    HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics,

  2. Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

    HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion

  3. Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

    HOUSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its lead

  4. Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

    HOUSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its corporate and financial

  5. MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data due 2020.
Seclidemstat
Solid tumors
Phase 1 maximum tolerated dose to be met in early 2020 with initial data due later that year.
Seclidemstat
Ewing sarcoma

Latest News

  1. Salarius Pharmaceuticals to Present at Biotech Showcase 2020

    HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics,

  2. Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

    HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion

  3. Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

    HOUSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its lead

  4. Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

    HOUSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its corporate and financial

  5. MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  6. Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

    HOUSTON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming

  7. Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children's Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

    HOUSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering

  8. Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

    HOUSTON, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the Safety Review Committees

  9. Salarius Pharmaceuticals Announces Senior Leadership Changes

    HOUSTON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to

  10. Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

    HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer

  11. Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

    HOUSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer